Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Valneva Se ADR (VALN)

33.71   2.06 (6.51%) 01-26 00:59
Open: 32.45 Pre. Close: 31.65
High: 36.62 Low: 31.92
Volume: 395,568 Market Cap: 1,806M
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 36.637 - 36.858 36.858 - 37.07
Low: 31.455 - 31.686 31.686 - 31.908
Close: 33.339 - 33.696 33.696 - 34.037

Technical analysis

as of: 2022-01-25 4:27:54 PM
Overall:       
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 56.74     One year: 69.97
Support: Support1: 30.26    Support2: 25.18
Resistance: Resistance1: 48.58    Resistance2: 59.90
Pivot: 37.87
Moving Average: MA(5): 37.18     MA(20): 42.19
MA(100): 43.50     MA(250):
MACD: MACD(12,26): -4.56     Signal(9): -3.90
Stochastic oscillator: %K(14,3): 14.54     %D(3): 23.15
RSI: RSI(14): 39.98
52-week: High: 67.84  Low: 24.16  Change(%): 27.6
Average Vol(K): 3-Month: 92  10-Days: 208

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
VALN has closed above bottom band by 21.5%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 24 Jan 2022
Valneva SE ADR (VALN) Down 4.84% in Premarket Trading - InvestorsObserver

Thu, 20 Jan 2022
Valneva SE ADR (VALN) is lower by 18.92% Thursday In Premarket Trading - InvestorsObserver

Wed, 19 Jan 2022
US stocks lower at close of trade; Dow Jones Industrial Average down 0.96% By Investing.com - Investing.com

Wed, 19 Jan 2022
Healthcare Stocks on the Move Wednesday: ZGNX, VVOS, VALN, GMVD, CRDF, OCX, PTPI, YMTX - InvestorsObserver

Wed, 19 Jan 2022
Valneva extends losses as EU regulator awaits more data on COVID-19 shot - Seeking Alpha

Tue, 11 Jan 2022
The Charles Schwab Corporation (SCHW) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 53
Shares Float (M) 31
% Held by Insiders
% Held by Institutions 0.62
Shares Short (K) 40
Shares Short P. Month (K) 24

Stock Financials

EPS -3.090
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 1.550
Profit Margin -113.86
Operating Margin -108.57
Return on Assets (ttm) -13.1
Return on Equity (ttm) -133.1
Qtrly Rev. Growth 91.4
Gross Profit (p.s.) -0.541
Sales Per Share 2.093
EBITDA (p.s.) -2.196
Qtrly Earnings Growth
Operating Cash Flow (M) 109
Levered Free Cash Flow (M) 62

Stock Valuations

PE Ratio -10.91
PEG Ratio
Price to Book value 21.75
Price to Sales 16.11
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.